{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:18Z","timestamp":1789429518475,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jacl.2014.12.005","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T18:54:29Z","timestamp":1419015269000},"page":"256-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of lipid-lowering medications in myasthenia gravis: A case report and literature review"],"prefix":"10.1016","volume":"9","author":[{"given":"Sophie C.","family":"Ragbourne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacl.2014.12.005_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2014.12.005_bib2","series-title":"[Ezetimibe for the Treatment of Primary Heterozygous-Familial and Non-familial Hypercholesterolemia Technology Appraisal Guidance 132]","year":"2009"},{"issue":"23","key":"10.1016\/j.jacl.2014.12.005_bib3","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.jacl.2014.12.005_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.jacl.2014.12.005_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"issue":"10","key":"10.1016\/j.jacl.2014.12.005_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2014.12.005_bib7","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1755-5922.2011.00267.x","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"10.1016\/j.jacl.2014.12.005_bib8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.jacl.2014.12.005_bib9","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacl.2014.12.005_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jacl.2014.12.005_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","article-title":"Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"22","author":"Simard","year":"2006","journal-title":"Can J Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2014.12.005_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-140-8-200404200-00034","article-title":"Ezetimibe and statin-associated myopathy","volume":"140","author":"Fux","year":"2004","journal-title":"Ann Intern Med"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2014.12.005_bib13","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2014.12.005_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2014.12.005_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"issue":"3","key":"10.1016\/j.jacl.2014.12.005_bib16","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1756-185X.2010.01481.x","article-title":"ANCA-positive vasculitis associated with simvastatin\/ezetimibe: expanding the spectrum of statin-induced autoimmunity?","volume":"13","author":"Sen","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.jacl.2014.12.005_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1997.00440250045006","article-title":"Drugs and myasthenia gravis. An update","volume":"157","author":"Wittbrodt","year":"1997","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jacl.2014.12.005_bib18","article-title":"Drugs Which May Exacerbate or Induce Myasthenia Gravis: A Clinician's Guide","volume":"10","author":"Ahmed","year":"2008","journal-title":"The Internet Journal of Neurology"},{"key":"10.1016\/j.jacl.2014.12.005_bib19","series-title":"Medications and Myasthenia Gravis: A Reference for Health Care Professionals","author":"Pascuzzi","year":"2000"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414004176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414004176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T17:26:56Z","timestamp":1537982816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287414004176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1933287414004176"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2014.12.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of lipid-lowering medications in myasthenia gravis: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2014.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}